NEW DELHI, (Economy India): Sun Pharmaceutical Industries Ltd, India’s largest pharmaceutical company, on Friday reported a 36.36% year-on-year decline in consolidated net profit to ₹1,988.53 crore for the second quarter of financial year 2026-27, citing one-time expenditure related to its proposed acquisition of Organon and litigation expenses in the United States.
The pharmaceutical major had reported a consolidated net profit of ₹3,124.95 crore in the corresponding quarter of the previous financial year, according to its regulatory filing.
Despite the decline in profitability, the company’s consolidated revenue from operations registered growth during the July-September quarter.
Sun Pharma Q2 Results: Revenue Grows 11.9%
Sun Pharma’s consolidated revenue from operations increased to ₹16,198.71 crore in Q2 FY27, compared with ₹14,478.31 crore in the year-ago quarter.
This represents year-on-year growth of approximately 11.9%, indicating higher reported revenue even as the company’s net profit came under pressure.
The difference between revenue growth and profit performance highlights the impact of the expenses cited by the company during the quarter.
Organon Acquisition Costs and US Litigation Expenses Impact Profit
The decline in quarterly profit was attributed to two key factors: one-time expenditure associated with the proposed acquisition of Organon and litigation expenses in the United States.
These expenses weighed on the company’s consolidated earnings for the September quarter.
The regulatory filing did not provide the individual amounts of these expenses in the information available for this report.
Sun Pharma Q2 FY27: Key Financial Figures
| Particulars | Q2 FY27 | Q2 FY26 |
|---|---|---|
| Consolidated net profit | ₹1,988.53 crore | ₹3,124.95 crore |
| Net profit growth | -36.36% | — |
| Revenue from operations | ₹16,198.71 crore | ₹14,478.31 crore |
| Revenue growth | +11.9% | — |
Revenue Growth Amid Earnings Pressure
Sun Pharma’s Q2 FY27 results reflect a quarter in which revenue from operations increased while consolidated net profit declined.
The proposed Organon acquisition-related expenditure and US litigation expenses were identified as factors affecting profitability. The company’s subsequent quarterly performance will be watched for further indications of how these costs influence earnings and financial results.
(Economy India)
